Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®
Interventions
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients aged at least 18 years who were suffering from symptoms of a COLD (naive or pre-treated) could be included in the PMS
Exclusion criteria
* Patients who meet one or more of the general or specific contraindications mentioned in the Summary of Product Characteristics (SmPC) are excluded from the Postmarketing Surveillance (PMS)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events | up to 8 weeks |
| Number of patients who premature discontinued therapy with Berodual® Respimat® | up to 8 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of patient satisfaction with regard to handling of Berodual® Respimat® inhaler | up to 8 weeks | by means of patient satisfaction and preference questionnaire (PASAPQ) |
Outcome results
None listed